For many years, depression has been viewed mainly as a disorder involving brain chemicals. Most commonly prescribed antidepressants work by changing levels of neurotransmitters such as serotonin and norepinephrine.
These medications have helped millions of people, but they are far from perfect. Many patients continue to experience significant symptoms even after trying multiple treatments.
Scientists are now exploring a different explanation for why some people develop depression. Increasingly, researchers believe that inflammation in the body may contribute to mental health problems in a subset of patients.
A new study published in JAMA Psychiatry suggests that targeting inflammation directly could potentially help people with difficult-to-treat depression.
The research was led by scientists at the University of Bristol and focused on a drug called tocilizumab. This medication is already widely used to treat autoimmune and inflammatory diseases, including rheumatoid arthritis. The drug works by blocking the activity of a protein called interleukin-6, which plays an important role in regulating immune responses.
The idea behind the study comes from years of research linking inflammation to depression. Scientists have observed that many people with depression have higher levels of inflammatory markers in their blood.
These markers indicate that the immune system may be more active than normal. Researchers suspect that this ongoing inflammation could affect brain function and contribute to symptoms such as low mood, fatigue, anxiety, and loss of motivation.
Previous genetic studies conducted by the same research group suggested that the IL-6 pathway may be directly involved in causing depression rather than simply being associated with it. This finding provided a strong reason to test whether blocking IL-6 could improve symptoms.
To investigate, researchers recruited 30 adults with treatment-resistant depression. These were people whose symptoms had not improved adequately despite conventional treatment. Importantly, participants also showed evidence of low-grade inflammation, making them ideal candidates for an immune-based therapy.
Participants were randomly assigned to receive either tocilizumab or a placebo. Neither the participants nor the researchers knew who received which treatment during the study. Over four weeks, the team monitored changes in depression severity, anxiety, fatigue, and quality of life.
The results suggested that the drug may have meaningful benefits. Although the study was too small to provide strong statistical certainty, participants receiving tocilizumab generally improved more than those receiving placebo. They reported lower depression severity, less fatigue, reduced anxiety, and better quality of life.
The remission results were particularly noteworthy. More than half of the patients receiving the drug achieved remission, compared with roughly one-third of those receiving placebo. While these numbers should be interpreted cautiously because of the small sample size, they provide a strong signal that further investigation is warranted.
The study reflects a broader trend in psychiatry toward precision medicine. Rather than assuming all depression has the same cause, researchers increasingly recognize that different biological processes may be involved in different people.
Some patients may primarily benefit from traditional antidepressants, while others may respond better to treatments targeting inflammation or other biological pathways.
If future studies confirm these findings, doctors may eventually use blood tests to identify patients whose depression is driven by inflammation. These individuals could then receive immune-targeted treatments designed specifically for their biological profile.
Researchers caution that the work is still at an early stage. Tocilizumab is not currently approved for treating depression, and much larger clinical trials are required before any changes to medical practice can be recommended.
Even so, the findings offer hope for people who have struggled for years with treatment-resistant depression. By expanding the search beyond traditional brain chemistry, scientists may be opening the door to entirely new treatment options.
Source: University of Bristol.
